HIV treatment dead end: US vaccine failures prompt end to trials
The trials, carried out by the National Institute of Allergy and
Infectious Diseases (NIAID), began in August 2009 and mark the
latest in a series of failed attempts at tackling the Human
Exactly 2,504 volunteers across 19 US cities – all gay men or transgendered people who had sex with men – participated in the massive federally backed study, which hoped to determine whether a vaccine program could prevent HIV infections or reduce the ‘viral load’: The amount of virus in the blood of infected patients.
The HVTN 505 vaccine was given to 1,250 participants, with 1,244 receiving a placebo. The volunteers were initially administered a series of three immunizations over the course of eight weeks. These DNA-based vaccines, designed to alert the immune system, were then followed up with a single ‘booster’ injection in the 24th week.
Results were analyzed on Monday, prompting a supervisory panel to swiftly halt the program. Forty-one infections were detected among those who had received the real vaccine, versus 30 in the placebo group.
Vaccines also failed to reduce infection levels in the blood. “The DSMB found that the vaccine failed to reduce viral load among volunteers who acquired HIV infection at least 28 weeks after entering the study,” the NIAID said in a statement released on Thursday.
Additionally, an increase in HIV acquisition was noted among
volunteers in the ‘investigational’ vaccine group, as opposed to
the placebo group. However, the NIAID said that this increase was
The institute went on to say that the results of the study are being scrutinized to determine both why the vaccine did not work and why there was an increase in HIV acquisition.
The search for an HIV cure has plagued scientists since the disease was first identified in the early 1980s. Some 34 million people are infected with the virus worldwide, including 3.4 million children.
In March, a baby girl born with HIV became the first person to be ‘functionally cured’ using conventional drugs, leading to speculation that the virus might be treatable in children.
“This trial has provided a clear, swift answer about a specific vaccine strategy. It’s not the answer we hoped for, but the search doesn't end here,” Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, said in a statement.